Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05450692
Title	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)
Acronym	LATIFY
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Docetaxel Ceralasertib + Durvalumab
Age Groups:	adult \| senior
Covered Countries	USA \| ROU \| POL \| NLD \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG